- Conditions
- Urea Cycle Disorder, Ornithine Transcarbamylase Deficiency, Citrullinemia 1, ARGI Deficiency, ASL Deficiency, Argininosuccinic Aciduria, ASS Deficiency, Hyperargininemia
- Interventions
- Not listed
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- 6 Years to 65 Years
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 5
- States / cities
- Aurora, Colorado • Washington D.C., District of Columbia • Philadelphia, Pennsylvania + 2 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 2113–2136
of 11,433
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Multiple Myeloma
- Interventions
- CC-92480, Bortezomib, Dexamethasone, Daratumumab, Carfilzomib, Elotuzumab, Isatuximab
- Drug
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 424 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 16
- States / cities
- Denver, Colorado • Tampa, Florida • Atlanta, Georgia + 10 more
- Conditions
- Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE), Pemphigus Vulgaris, Multiple Sclerosis (MS), Systemic Sclerosis (SSc), Pediatric SLE, Juvenile Idiopathic Arthritis (JIA), Juvenile Dermatomyositis (JDM), Pediatric-Onset Multiple Sclerosis (POMS)
- Interventions
- Moderna mRNA-1273, BNT162b2, Ad26.COV2.S, Continue IS (MMF or MPA), Continue IS (MTX), Continue IS (B cell depletion therapy), Monovalent [B.1.351] CoV2 preS dTM-AS03, Withhold IS (MMF or MPA), Withhold IS (MTX), Withhold IS (B cell depletion therapy), Moderna mRNA-1273, Bivalent, BNT162b2, Bivalent
- Biological · Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 2 Years and older
- Enrollment
- 258 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 29
- States / cities
- Los Angeles, California • New Haven, Connecticut • Atlanta, Georgia + 18 more
- Conditions
- Crohn's Disease (CD)
- Interventions
- ABT-494
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 107 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2025
- U.S. locations
- 27
- States / cities
- La Jolla, California • San Francisco, California • Gainesville, Florida + 22 more
- Conditions
- HIV Infections
- Interventions
- VRC-HIVDNA009-00-VP, VRC-HIVADV014-00-VP
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 90 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006 – 2012
- U.S. locations
- 6
- States / cities
- Birmingham, Alabama • Boston, Massachusetts • New York, New York + 2 more
- Conditions
- Dental Anxiety
- Interventions
- Flumazenil, Placebo
- Drug
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years to 40 Years
- Enrollment
- 14 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006 – 2007
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- Liraglutide, Golimumab
- Drug
- Lead sponsor
- Carla Greenbaum, MD
- Other
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 2
- States / cities
- Idaho Falls, Idaho • Seattle, Washington
- Conditions
- Asthma
- Interventions
- Placebo, FP 100mcg, FP 250mcg, FP 500mcg, FSC 100/50mcg, FSC 250/50mcg, FSC500/50mcg
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 446 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2004
- U.S. locations
- 51
- States / cities
- Birmingham, Alabama • Jasper, Alabama • Glendale, Arizona + 43 more
- Conditions
- Anatomic Stage IV Breast Cancer AJCC v8, HER2 Positive Breast Carcinoma, Metastatic Breast Carcinoma, Refractory Breast Carcinoma
- Interventions
- Alpha-tocopheryloxyacetic Acid, Trastuzumab
- Drug · Biological
- Lead sponsor
- Veana Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2030
- U.S. locations
- 2
- States / cities
- Portland, Oregon • Seattle, Washington
- Conditions
- Non-small Cell Lung Cancer (NSCLC)
- Interventions
- iSABR, 25 Gray in 1 fraction for small peripheral tumors, iSABR, 50 Gray in 4 fractions for medium peripheral tumors, iSABR, 54 Gray in 3 fractions for large peripheral tumors, iSABR, 40 Gray in 4 fractions for small central tumors, iSABR, 50 Gray in 4 fractions for medium central tumors, iSABR, 60 Gray in 8 fractions for large central tumors
- Radiation
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 256 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2022
- U.S. locations
- 2
- States / cities
- Stanford, California • Seattle, Washington
- Conditions
- Spinal Cord Injuries
- Interventions
- Transcutaneous Spinal Cord Stimulation, Sham Stimulation
- Device
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 21 Years to 65 Years
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Kidney Stones, Nephrolithiasis, Urolithiasis
- Interventions
- Propulse 1 with C5-2 probe, Propulse 1 with SC-X probe
- Device
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 172 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2026
- U.S. locations
- 2
- States / cities
- Seattle, Washington
- Conditions
- Type 1 Diabetes (T1D), Metabolic Diseases, Glucose Metabolism Disorders, Endocrine System Diseases, Autoimmune Diseases, Immune System Diseases, Diabetes Melletus, Type 1, Nutritional and Metabolic Diseases, Combination Therapy
- Interventions
- AMX0035, Placebo
- Drug
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years to 69 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Neuroblastoma
- Interventions
- aldesleukin, therapeutic autologous lymphocytes, chemotherapy, ganciclovir
- Biological · Drug
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- 1 Year to 17 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2005
- U.S. locations
- 2
- States / cities
- Duarte, California • Seattle, Washington
- Conditions
- Septic Shock
- Interventions
- Not listed
- Lead sponsor
- Seattle Children's Hospital
- Other
- Eligibility
- 1 Month to 18 Years
- Enrollment
- 389 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 11
- States / cities
- Phoenix, Arizona • Los Angeles, California • Washington D.C., District of Columbia + 7 more
- Conditions
- Post-Operative Atrial Fibrillation
- Interventions
- AtriClip® Gillinov-Cosgrove™ LAA Exclusion Systems, Anticoagulation Therapy
- Device · Drug
- Lead sponsor
- AtriCure, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 562 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 22
- States / cities
- San Diego, California • Stanford, California • Orlando, Florida + 15 more
- Conditions
- Prostate Cancer
- Interventions
- Plenaxis
- Drug
- Lead sponsor
- PRAECIS Pharmaceuticals Inc.
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 2,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2008
- U.S. locations
- 60
- States / cities
- Birmingham, Alabama • Goodyear, Arizona • Phoenix, Arizona + 54 more
- Conditions
- Depressive Disorder, Major, Unipolar Depression
- Interventions
- Deep Brain Stimulation, Libra Deep Brain Stimulation System
- Device
- Lead sponsor
- Abbott Medical Devices
- Industry
- Eligibility
- 21 Years to 70 Years
- Enrollment
- 125 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2015
- U.S. locations
- 11
- States / cities
- Stanford, California • Chicago, Illinois • Worcester, Massachusetts + 8 more
- Conditions
- Carpal Tunnel Syndrome
- Interventions
- Early Carpal Tunnel Release for Mild or Moderate CTS, MR Nerve Imaging for CTS
- Procedure · Other
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 116 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2008
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Hemostasis, Oral Contraceptive
- Interventions
- 91-day Levonorgestrel Oral Contraceptive, 28-day Levonorgestrel Oral Contraceptive, 28-day Desogestrel Oral Contraceptive
- Drug
- Lead sponsor
- Teva Women's Health
- Industry
- Eligibility
- 18 Years to 40 Years · Female only
- Enrollment
- 265 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2011
- U.S. locations
- 21
- States / cities
- San Diego, California • Washington D.C., District of Columbia • Miami, Florida + 16 more
- Conditions
- Hodgkin Lymphoma
- Interventions
- brentuximab vedotin, doxorubicin, vinblastine, dacarbazine, G-CSF, nivolumab
- Drug
- Lead sponsor
- Seagen Inc.
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 255 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 55
- States / cities
- Fountain Valley, California • Aurora, Colorado • Colorado Springs, Colorado + 48 more
- Conditions
- Substance-Related Disorders, Hepatitis
- Interventions
- Pegylated Interferon
- Drug
- Lead sponsor
- National Institute on Drug Abuse (NIDA)
- NIH
- Eligibility
- 15 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2007
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Hematologic Malignancies, Inherited Disorders of Metabolism, Inherited Abnormalities of Platelets, Histiocytic Disorders, Acute Myelogenous Leukemia (AML or ANLL), Acute Lymphoblastic Leukemia (ALL), Other Acute Leukemia, Chronic Myelogenous Leukemia (CML), Myelodysplastic (MDS) / Myeloproliferative (MPN) Diseases, Other Leukemia, Hodgkin Lymphoma, Non-hodgkin Lymphoma, Multiple Myeloma/ Plasma Cell Disorder (PCD), Inherited Abnormalities of Erythrocyte Differentiation or Function, Disorders of the Immune System, Autoimmune Diseases, Severe Aplastic Anemia
- Interventions
- A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs)
- Drug
- Lead sponsor
- Center for International Blood and Marrow Transplant Research
- Network
- Eligibility
- Not listed
- Enrollment
- 99,999 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2041
- U.S. locations
- 142
- States / cities
- Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 90 more
- Conditions
- Cystic Fibrosis
- Interventions
- TEZ, IVA, VX-440, Matched Placebo
- Drug
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 74 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 22
- States / cities
- Tucson, Arizona • Palo Alto, California • San Francisco, California + 18 more